Andrew J. Lucke

2.2k citations

36 papers · 1.7k indexed · 1 hit paper · h-index 22

Pharmaceutical Science top 2%
Microbiology top 5%
- Antimicrobial Peptides and Activities 4
Rheumatology top 5%
Molecular Biology top 10%
- Histone Deacetylase Inhibitors Research 13
- Chemical Synthesis and Analysis 7
- Protein Degradation and Inhibitors 5
Organic Chemistry top 5%
- Click Chemistry and Applications 5
Oncology
- Peptidase Inhibition and Analysis 4
Infectious Diseases
- HIV/AIDS drug development and treatment 4
Electrical and Electronic Engineering
- Molecular Junctions and Nanostructures 3

Co-authors: David P. Fairlie Nicole Gerwin Weijun Xu Daniel S. Nielsen Martin J. Stoermer Nicholas E. Shepherd Huy N. Hoang Katherine T. Andrews
Cited by: Pharmaceutical Science Microbiology Rheumatology
Journals: Chemical Reviews (1 paper)Journal of the American Chemical Society (1 paper)Angewandte Chemie International Edition (1 paper)
Partner nations: Australia United Kingdom United States

In The Last Decade

Andrew J. Lucke

36 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Andrew J. Lucke

Since Specialization

Citations

This map shows the geographic impact of Andrew J. Lucke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. Lucke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. Lucke more than expected).

Fields of papers citing papers by Andrew J. Lucke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. Lucke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. Lucke. The network helps show where Andrew J. Lucke may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew J. Lucke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew J. Lucke Line = papers co-authored together Andrew J. Lucke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Temporal perturbation of histone deacetylase activity reveals a requirement for HDAC1–3 in mesendoderm cell differentiation Cell Reports ·Enakshi Sinniah,Zhixuan Wu,Sophie Shen,Marina Naval-Sánchez,Xiaoli Chen,Junxian Lim,Abbigail Helfer,Abishek Iyer,Jiahui Tng,Andrew J. Lucke,Robert C. Reid,Meredith A. Redd,Christian M. Nefzger,David P. Fairlie,Nathan J. Palpant	2022	3
2	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates Journal of Medicinal Chemistry ·Jeffrey Y. W. Mak,Kai‐Chen Wu,Praveer Gupta,Sheila Barbero,Maddison G. McLaughlin,Andrew J. Lucke,Jiahui Tng,Junxian Lim,Zhixuan Loh,Matthew J. Sweet,Robert C. Reid,Ligong Liu,David P. Fairlie	2021	19
3	Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice International Journal for Parasitology Drugs and Drug Resistance ·Ming Jang Chua,Jiahui Tng,Eva Hesping,Gillian M. Fisher,C.D. Goodman,Tina S. Skinner‐Adams,Darren Do,Andrew J. Lucke,Robert C. Reid,David P. Fairlie,Katherine T. Andrews	2021	5
4	Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation Journal of Medicinal Chemistry ·Jiahui Tng,Junxian Lim,Kai‐Chen Wu,Andrew J. Lucke,Weijun Xu,Robert C. Reid,David P. Fairlie	2020	22
5	A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy Cellular and Molecular Gastroenterology and Hepatology ·Yonghua Sheng,Rabina Giri,Julie Davies,Veronika Schreiber,Saleh Alabbas,Ramya Movva,Yaowu He,Andy Wu,John D. Hooper,Brett McWhinney,Iulia Oancea,Gregor Kijanka,Sumaira Z. Hasnain,Andrew J. Lucke,David P. Fairlie,Michael A. McGuckin,Timothy H. Florin,Jakob Begun	2020	15
6	Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis Disease Models & Mechanisms ·Soo-Hyun Kim,Richard P. Redvers,Lap Hing,Xiawei Ling,Andrew J. Lucke,Robert C. Reid,David P. Fairlie,Ana Carolina Baptista Moreno Martin,Robin L. Anderson,Delphine Denoyer,Normand Pouliot	2018	24
7	Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina International Journal for Parasitology Drugs and Drug Resistance ·Neil H. Bagnall,Barney M. Hines,Andrew J. Lucke,Praveer Gupta,Robert C. Reid,David P. Fairlie,Andrew C. Kotze	2017	10
8	Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets Journal of Molecular Graphics and Modelling ·Weijun Xu,Andrew J. Lucke,David P. Fairlie	2015	57
9	Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery Journal of Chemical Information and Modeling ·Samuel R. Perry,Weijun Xu,Anna Wirija,Junxian Lim,Mei‐Kwan Yau,Martin J. Stoermer,Andrew J. Lucke,David P. Fairlie	2015	12
10	Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable Angewandte Chemie International Edition ·Daniel S. Nielsen,Huy N. Hoang,Rink‐Jan Lohman,Timothy A. Hill,Andrew J. Lucke,David J. Craik,David J. Edmonds,David A. Griffith,Charles J. Rotter,Roger B. Ruggeri,David A. Price,Spiros Liras,David P. Fairlie	2014	118
11	Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro Journal of Cellular Physiology ·Melissa Cantley,David P. Fairlie,P. Mark Bartold,K. D. Rainsford,G. T. Le,Andrew J. Lucke,C.A. Holding,David R. Haynes	2011	65
12	Histone deacetylase inhibitors and periodontal bone loss Journal of Periodontal Research ·Melissa Cantley,P. Mark Bartold,V. Marino,David P. Fairlie,G. T. Le,Andrew J. Lucke,David R. Haynes	2011	57
13	Inhibitors selective for HDAC6 in enzymes and cells Bioorganic & Medicinal Chemistry Letters ·Praveer Gupta,Robert C. Reid,Ligong Liu,Andrew J. Lucke,Steve Broomfield,Melanie R. Andrews,Matthew J. Sweet,David P. Fairlie	2010	27
14	Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components Bioorganic & Medicinal Chemistry Letters ·Nicole C. Wheatley,Katherine T. Andrews,Truc Linh Tran,Andrew J. Lucke,Robert C. Reid,David P. Fairlie	2010	34
15	Amyloid Formation from an α‐Helix Peptide Bundle Is Seeded by 3₁₀‐Helix Aggregates Chemistry - A European Journal ·Yogendra Singh,Philip C. Sharpe,Huy N. Hoang,Andrew J. Lucke,Alasdair W. McDowall,Stephen Bottomley,David P. Fairlie	2010	32
16	New Cysteine Derivatives with Antiproliferative Activity on Melanoma Cells Medicinal Chemistry ·David P. Fairlie,Peter G. Parsons,Andrew J. Lucke,Glen M. Boyle	2006	1
17	Structural Mimicry of Two Cytochromeb₅₆₂Interhelical Loops Using Macrocycles Constrained by Oxazoles and Thiazoles Journal of the American Chemical Society ·Yogendra Singh,Martin J. Stoermer,Andrew J. Lucke,Tom Guthrie,David P. Fairlie	2005	32
18	Designing supramolecular structures from models of cyclic peptide scaffolds with heterocyclic constraints Journal of Molecular Graphics and Modelling ·Andrew J. Lucke,Joel D. A. Tyndall,Yogendra Singh,David P. Fairlie	2003	25
19	Acylation of peptides by lactic acid solutions European Journal of Pharmaceutics and Biopharmaceutics ·Andrew J. Lucke	2003	40
20	The regiochemistry of cyclopropylcarbinylstannane ring fission Tetrahedron Letters ·Andrew J. Lucke,David James Young	1994	2

About Andrew J. Lucke

Andrew J. Lucke is a scholar working on Microbiology, Bioengineering and Molecular Biology, having authored 36 papers that have together received 1.7k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (13 papers), Chemical Synthesis and Analysis (7 papers), Click Chemistry and Applications (5 papers), Protein Degradation and Inhibitors (5 papers), Antimicrobial Peptides and Activities (4 papers), Peptidase Inhibition and Analysis (4 papers), HIV/AIDS drug development and treatment (4 papers) and Molecular Junctions and Nanostructures (3 papers). The work is most often cited by research in Pharmaceutical Science (143 citations), Microbiology (122 citations) and Rheumatology (237 citations). Andrew J. Lucke has collaborated with scholars based in Australia, United Kingdom and United States. Frequent co-authors include David P. Fairlie, Nicole Gerwin, Weijun Xu, Daniel S. Nielsen, Martin J. Stoermer, Nicholas E. Shepherd, Huy N. Hoang, Katherine T. Andrews, Yogendra Singh and Timothy A. Hill. Their work appears in journals such as Chemical Reviews, Journal of the American Chemical Society and Angewandte Chemie International Edition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact